Prevalence of the fibrinogen β-chain, angiotensin-converting enzyme and plasminogen activator inhibitor-1 polymorphisms in Costa Rican young adults with thrombotic disease

被引:1
|
作者
Hidalgo, Andrea [1 ]
Salazar-Sanchez, Lizbeth [1 ]
Cartin, Mayra [2 ]
Mendez, Max [1 ]
Arauz, Jorge [3 ]
Parajeles, Alexander [4 ]
机构
[1] Univ Costa Rica, CIHATA, Hosp San Juan de Dios, San Jose 106341000, Costa Rica
[2] Univ Costa Rica, Publ Healthy Sch, San Jose 106341000, Costa Rica
[3] San Juan de Dios Hosp, Dept Cardiol, San Jose, Costa Rica
[4] San Juan de Dios Hosp, Dept Neurol, San Jose, Costa Rica
关键词
polymorphisms; fibrinogen; plasminogen activator inhibitor-1; thrombosis; angiotensin-converting enzyme; CORONARY-ARTERY-DISEASE; INSERTION DELETION POLYMORPHISM; PAI-1 PROMOTER POLYMORPHISM; MYOCARDIAL-INFARCTION; GENE POLYMORPHISM; CARDIOVASCULAR-DISEASE; CEREBROVASCULAR-DISEASE; HEART-DISEASE; RISK; REGION;
D O I
10.1002/cbf.1655
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Thrombotic disease is a multifactorial condition that involves both classical and genetic risk factors. We studied the association between the classical risk factors of hypertension and smoking, and polymorphisms on the genes of the angiotensin-converting enzyme (ACE), the p-chain of fibrinogen (FG), and the plasminogen activator inhibitor-1 (PAI-1) in patients with venous and arterial thrombosis. The present investigation is a retrospective case-control study. A total of 340 participants were analyzed, including 162 patients and 178 healthy controls. Hypertension and smoking showed a significant association with thrombotic disease (p < 0.05) but FG level was found significant risk factor only for the venous thrombosis (VT) group (p < 0.04). Significant differences between thrombotic groups were found for the studied polymorphisms of PAI-1 (p < 0.0014). but for both FG beta-chain gene polymorphisms, none of the molecular analyses showed a positive sample for any mutating allele (p > 0.05). For the ACE polymorphism, the I allele present a protective effect in the general thrombotic group. This is one of the first reports in a Latin-American population dealing with these molecular markers and thrombotic diseases. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:367 / 373
页数:7
相关论文
共 50 条
  • [21] Angiotensin converting enzyme insertion/deletion polymorphism is associated with plasma antigen levels of plasminogen activator inhibitor-1 in healthy Japanese population
    Matsubara, Y
    Hayakawa, T
    Tsuda, T
    Takeshita, E
    Watanabe, G
    Murata, M
    Watanabe, K
    Ikeda, Y
    BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (02) : 115 - 120
  • [22] Association of Plasminogen Activator Inhibitor-1 4G/5G and Angiotensin-Converting Enzyme I/D Polymorphisms with Recurrent Pregnancy Loss in Sudanese Women: A Case-Control study
    Ahmed, Hanan K.
    Elgoraish, Amanda G.
    Abdalla, Selma Elmalieh
    Babker, Asaad MA.
    Alfeel, Ayman Hussien
    Abbas, Amin Omer Ibrahim
    Mohamedahmed, Khalid Abdelsamea
    Elzaki, Salaheldein G.
    INTERNATIONAL JOURNAL OF BIOMEDICINE, 2023, 13 (01) : 127 - 133
  • [23] Angiotensinogen, angiotensine converting enzyme and plasminogen activator inhibitor-1 gene polymorphism in chronic allograft dysfunction
    Negar Azarpira
    M. Bagheri
    Gh. A. Raisjalali
    M. H. Aghdaie
    S. Behzadi
    H. Salahi
    M. Rahsaz
    M. Darai
    M. J. Ashraf
    B. Geramizadeh
    Molecular Biology Reports, 2009, 36 : 909 - 915
  • [24] Association between plasminogen activator inhibitor-1 gene polymorphisms and susceptibility to Parkinson's disease in Chinese patients
    Xu, Qi
    Lai, Qilun
    Wang, Junjun
    Zhuang, Liying
    Cheng, Lin
    Mo, Yejia
    Liu, Lu
    Zhao, Zexian
    Zhang, Ying
    Weng, Shiting
    Qiao, Song
    ACTA NEUROLOGICA BELGICA, 2022, 122 (06) : 1557 - 1566
  • [25] Lack of association between the angiotensin-converting enzyme insertion/deletion polymorphism and plasminogen activator inhibitor-1 antigen levels in the National Heart, Lung, and Blood Institute Family Heart Study
    Pankow, JS
    Arnett, DK
    Borecki, IB
    Hunt, SC
    Eckfeldt, JH
    Folsom, AR
    Djoussé, L
    BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (06) : 551 - 558
  • [26] Plasminogen Activator Inhibitor-1 Polymorphisms and Risk of Coronary Artery Disease: Evidence From Meta-Analysis and Trial Sequential Analysis
    Tabaei, Samira
    Omraninava, Melodi
    Mehranfar, Sahar
    Motallebnezhad, Morteza
    Tabaee, Seyedeh Samaneh
    BIOCHEMICAL GENETICS, 2022, 60 (05) : 1409 - 1445
  • [27] Combinations of fibrinolytic gene polymorphisms (plasminogen activator inhibitor type 1 4G/5G, factor XIII Val34Leu and angiotensin-converting enzyme I/D) in women with idiopathic infertility
    Velickovic, Jelena
    Jelicic, Mihajlo
    Stojkovic, Oliver
    BLOOD COAGULATION & FIBRINOLYSIS, 2021, 32 (02) : 103 - 107
  • [28] Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker
    Ishibashi, Ken
    Kurisu, Satoshi
    Kato, Yasuko
    Mitsuba, Naoya
    Dohi, Yoshihiro
    Nishioka, Kenji
    Kihara, Yasuki
    HEART AND VESSELS, 2013, 28 (01) : 7 - 11
  • [29] The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population
    Park, Han Sung
    Sung, Jung-Hoon
    Ryu, Chang Soo
    Lee, Jeong Yong
    Ko, Eun Ju
    Kim, In Jai
    Kim, Nam Keun
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (04): : 1 - 13
  • [30] Contribution of Deletion in Angiotensin-converting Enzyme But Not A1166C Angiotensin II Type-1 Receptor Gene Polymorphisms to Clinical Outcomes in Atherothrombotic Disease
    Le Hello, Claire
    Fradin, Sabine
    Morello, Remy
    Coffin, Olivier
    Maiza, Dominique
    Hamon, Martial
    ARCHIVES OF MEDICAL RESEARCH, 2011, 42 (03) : 202 - 210